Navigation Links
Human Embryonic-Like Extracellular Matrix Significantly Inhibits Tumor Growth and Cancer Cell Proliferation
Date:6/17/2010

hown the ability of the hECM, when used to coat biopsy needles, to significantly reduce tumor seeding along the needle track (p=0.002) and prevent the development of secondary subcutaneous tumors. This represents a potential nearer-term application of the hECM in oncology.

"Our studies with hECM substantiate various reports which have shown that embryonic matrix proteins can selectively target the growth of cancer cells in vivo," said Emmett Pinney, Histogen's Director of Oncology. "We are excited about demonstrating the efficacy of our embryonic-like ECM proteins in vivo and about the range of potential applications of the hECM, such as a biopsy needle coating, and as a post-resection tissue filler to improve healing and to prevent possible recurrence or metastasis."

The inhibitory affect of the hECM is selective for malignant cells, supporting fibroblast expansion while concurrently inhibiting mesothelioma cells in vitro. Preliminary indications point to the activation of apoptotic enzymes, as seen through caspase upregulation, leading to apoptosis, or programmed cancer cell death.

"Human embryonic-like ECM stimulates proliferation and differentiation in stem cells while killing cancer cells" will be presented by Histogen CEO Dr. Gail Naughton at the ISSCR Annual Meeting, taking place June 16-19, 2010 in San Francisco.

About Histogen
Histogen, launched in 2007, seeks to redefine regenerative medicine by developing a series of high value products that do not contain embryonic stem cells or animal components. Through Histogen's proprietary bioreactors that mimic the embryonic environment, newborn cells are encouraged to naturally produce the vital proteins and growth factors from which the Company has developed its rich product portfolio. Histogen has two product families - a proprietary liquid complex of embryonic-like proteins and growth factors, and a human Extracellular Matrix (ECM) materi
'/>"/>

Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Page: 1 2 3

Related biology technology :

1. Expiry of Hart-Scott-Rodino Waiting Period for JUVISTA(R) (Human TGF BETA 3)
2. New Initiative Has Shocking Effect: Thousands of Missourians with Abnormal Chromosome Structures Are Not Human
3. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
4. Human Genome Sciences Announces $40 Million Milestone Payment Related to Albuferon(R) Development
5. Novocell Announces Discovery Linking Key Cancer Cell Signaling Pathways With Proliferation and Self-Renewal of Human Embryonic Stem Cells
6. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Thomas Weisel Partners Conference
7. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at BioCentury-Thomson Financial Investment Conference
8. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Bear Stearns Conference
9. Human Pheromone Sciences Enters Into Agreement to Reposition and Promote its Natural Attraction(R) Brand
10. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Merrill Lynch Conference
11. Premier Research Appoints Global Head of Human Resources
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Human Embryonic-Like Extracellular Matrix Significantly Inhibits Tumor Growth and Cancer Cell Proliferation 
(Date:7/30/2015)... , CA (PRWEB) , ... July 30, 2015 ... ... the successful completion of a field clinical study of its canine osteoarthritis stem ... together with Aratana Therapeutics (Kansas City, KS) and will be marketed in the ...
(Date:7/30/2015)... July 30, 2015 Ascendis Pharma A/S ... applies its innovative TransCon technology to address significant ... from a six-month Phase 2 study to evaluate ... Hormone in 53 treatment-naïve, pre-pubertal children with growth ... extremely pleased with the top-line results from our ...
(Date:7/30/2015)... ... 30, 2015 , ... GEA's Pony™ NS2006L is ... up to 1500 bar. The sanitary design gauge of the NS2006L is well ... The Pony™ NS2006L homogenizer is an ideal solution for the processing of ...
(Date:7/29/2015)... US-Australian drug discovery company, Novogen Limited (ASX: NRT; NASDAQ: ... progressing its ground-breaking technology platforms to Phase 1 clinical ... Company delivers the best value for shareholders. ... the Company currently had an extensive program of activities ... academic partnerships and initiatives, and he was working with ...
Breaking Biology Technology:VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7GEA Announces the Pony™ NS2006L… a Self-contained, High Pressure Lab Homogenizer for Product Development Ensuring Maximum Efficiency and Safety 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 3Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 4Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 5Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 6Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 7Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 8Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 9Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 10
... Keryx Biopharmaceuticals,Inc. (Nasdaq: KERX ) today announced ... present an overview of the Company,s cancer,pipeline at ... Conference,in San Francisco. Dr. Henderson,s presentation will take ... Dr. Henderson,s presentation will be webcast live ...
... 17 BioMed Realty Trust, Inc.,(NYSE: BMR ) ... a,third quarter 2007 dividend of $0.31 per share of ... of $1.24 per common share. BioMed also announced ... $0.46094 per share of the company,s 7.375% Series A ...
... Surgery at the Forefront, SACRAMENTO, Calif., Sept. ... has formed a new company, Curexo Medical, Inc.,(CMI), ... Surgical Services,Inc. (ISS). Under the licensing agreement, Curexo, ... to CMI. Curexo Medical, Inc., located in ...
Cached Biology Technology:Keryx Biopharmaceuticals to Present at Bank of America Investment Conference 2BioMed Realty Trust Declares Third Quarter 2007 Common Stock and Preferred Stock Dividends 2New Orthopedic Surgical Robotics Company Opens Its Doors; Files with the FDA for Clearance of Its Flagship Product 2
(Date:7/21/2015)... YORK , July 21, 2015 ... systems, as seen in the recent U.S. Office ... a solution to the infosec conundrum, but developers ... is stored. To address this dilemma, Biometrics-as-a-Service provider ... its Biometric Tokenization SDK for third party integration. ...
(Date:7/13/2015)... SAN JOSE, Calif. , July 13, 2015 ... the leading developer of human interface solutions, today ... second generation touch and display driver integration (TDDI) ... solution is the first to combine Synaptics , ... expertise with proven display driver technology developed in ...
(Date:7/9/2015)... SAN JOSE, Calif. , July 9, 2015 /PRNewswire/ ... human interface solutions, announced today that it will report ... 2015 on Thursday, July 30, 2015 after the close ... call for analysts and investors at 2:00 p.m. PT ... information.    To participate on the live ...
Breaking Biology News(10 mins):HYPR Corp. Launches Industry First Biometric Tokenization Platform 2HYPR Corp. Launches Industry First Biometric Tokenization Platform 3HYPR Corp. Launches Industry First Biometric Tokenization Platform 4Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2
... This news release is available in French ... 2013 From office towers to shopping malls, educational institutions to ... all electricity consumed in Canada. Thanks to new research funding for ... and source of pollution. More than $2 million in funding ...
... in Florence last week. It provided us with some of the ... Did life begin on Mars rather than on earth?, Chelyabinsk meteor ... Bird", was probably a herbivore Goldschmidt2014 is due to ... so if you want to attend, put the dates in your ...
... planarian flatworms have the remarkable ability to regrow any missing ... study the molecular basis of regeneration. Over ... that differ depending on the severity of the injury they ... puncture wound reacts at the cellular and molecular levels quite ...
Cached Biology News:Buildings of the future 2Tissue loss triggers regeneration in planarian flatworms 2